Pertussis cost-effectiveness of therapy

• Given the morbidity of of Pertussis, the cost-effectiveness of treatment is substantial.
  • A retrospective assessment of medical costs of confirmed pertussis in 936 adults in Massachusetts during 1998 to 2000, and a prospective assessment of nonmedical costs in 203 adults during 2001 to 2003 indicated that the mean medical and nonmedical cost per case was $326 and $447, respectively, for a societal cost of $773.^{_Prevention_of_pertussis,_tetanus,_and_diphtheria_among_pregnant_and_postpartum_women_and_their_infants._Recommendations_of_the_Advisory_Committee_on_Immunization_Practices_(ACIP).-1|[1]}
  • If the cost of antimicrobials to treat contacts and the cost of personal time were included, the societal cost could be as high as $1,952 per adult case.^{_Prevention_of_pertussis,_tetanus,_and_diphtheria_among_pregnant_and_postpartum_women_and_their_infants._Recommendations_of_the_Advisory_Committee_on_Immunization_Practices_(ACIP).-1|[1]}

• Cost-benefit and cost-effectiveness analyses of adult Tdap vaccination have varied in their results. When discrepancies in the models were addressed, an adult Tdap vaccination program was cost-effective when incidence of pertussis exceeded 120 cases per 100,000 population, using a benchmark of $50,000 per quality-adjusted life year saved. ^[2]

Template:WH Template:WS